Cephalon, Inc.
Overview
Cephalon has a cabinet stocked with specialty drugs. The company's research, development, manufacturing, and marketing activities focus on therapies for central nervous system (CNS) disorders, cancer, pain, and inflammatory disease. Its NUVIGIL and PROVIGIL drugs treat the sleep disorder narcolepsy. The company's other top sellers are cancer drug TREANDA, cancer pain medications ACTIQ and FENTORA, epilepsy treatment GABITRIL, and muscle relaxant AMRIX. It also markets some generic pharmaceuticals. While the firm's products are primarily sold in the US and Europe, its medicines are available in some 100 countries. Cephalon was acquired by top generic drugmaker Teva Pharmaceutical Industries in 2011.
Sample Overview & HistoryKey Numbers from Hoover's UK
Key financials for Cephalon, Inc.
| Company Type | Subsidiary of Teva |
|---|---|
| Fiscal Year-End | December |
| 2010 Sales (mil.) | £1,817.1 |
| 1-Year Sales Growth | 28.2% |
| 2010 Net Income (mil.) | £275.2 |
| 1-Year Net Income Growth | 24.3% |
| 2010 Employees | 3,726 |
| 1-Year Employee Growth | 23.1% |
Key People from Hoover's UK
Key people and executives for Cephalon, Inc.
| Chairman | William P. (Bill) Egan (Subscribers see complete biographies -- view sample)
|
|---|---|
| CEO and Director | J. Kevin Buchi |
| EVP and CFO | Wilco Groenhuysen |
Top Competitors from Hoover's UK
Top competitors of Cephalon, Inc.
There are 32 competitors for Cephalon; see more.Significant Developments
View company events at Cephalon, Inc. such as IPOs, bankruptcies, or executive changes
| Event | Details |
|---|---|
| Top Executive Change | Subscribers get full details -- view a sample |
| Top Executive Change | |
| Top Executive Change |
Industry Information from Hoover's UK
First Research Industry Profiles Extensive Industry Intelligence
Hoover's Industries
- Pharmaceuticals(primary)
Rankings from Hoover's UK
See how Cephalon, Inc. ranks in standard industry listings such as Fortune 500, S&P 500, and Dow Jones
